Austin-based Firmspace opened its Houston location last year. Courtesy of Firmspace

Before the pandemic, Houston coworking demand mirrored that of the rest of the country: shared space was booming, new operators were opening up. Demand was growing in Houston, as it was in other markets.

When the pandemic arrived in Houston last spring, the city was hit with a crisis on two fronts: local public health challenges due to the arrival of COVID-19 were further complicated by a downturn in the price of oil and gas industry — the literal fuel of this city's dominant industry.

But coworking hasn't faded away as office spaces closed or reduced capacity – it's evolved. In fact, the ongoing pandemic has accelerated this changing space and pushed operators to adapt their offerings to meet the market's needs. The result in Houston is the emergence of three major trends that we expect to see persist beyond 2021.

Increased demand for private offices

According to a recent report from JLL, up to 70 percent of all office spaces were primarily or partially open plan in design by the first quarter of 2020. But few of us want to sit in an open plan office with a dozen other masked professionals while fielding Zoom calls, but working from home isn't an option for those who lack the space and privacy they need to effectively work from home.

This combination of pandemic-related stressors has driven more Houstonians to seek out private office space for rent. The basic requirements in the pandemic era look slightly different than what we might have observed a year ago. Professionals want:

  • Private office spaces with doors that close and lock
  • Walls that provide privacy and noise insulation
  • Secure IT infrastructure, chiefly high-speed internet access
  • Enhanced cleaning protocols in common spaces and high-touch areas
  • Closed ventilation loops and as much clean air piped in from the outdoors as possible

And coworking spaces are doing their best to deliver this calm, safe environment where busy professionals can come to do focused work.

More short-term arrangements

The future has never looked more uncertain to professionals and leadership in all sectors. Here at the end of 2020, many companies that have paid nearly nine months of rent on office space that they've been unable to safely use are weighing the benefits of breaking their years-long commercial leases.

Companies are not sure what the structure of their teams will be in three months, nevermind three years, and this is changing how leaders think about their real estate contracts. In this climate, many are turning to coworking spaces that offer six- and 12-month contracts with furnishes and IT infrastructure in place to lighten their financial commitments to physical spaces.

The other trend in short-term leasing that local coworking spaces have embraced is the day office. Given that many of us are planning to work at least part-time from our home offices for the near future, coworking spaces have spotted the opportunity to offer a pay-per-day model to engage professionals that only need a break from the home office one or two days a week.

A private office as a status symbol

The office used to be where we went to get away from home five days a week. For members of traditional coworking spaces in the startup and tech industries, the office often felt like an incubator where spontaneous connections happened.

But in light of the pandemic, private office space has become a refuge where professionals go to feel safe, achieve focused work, and execute sensitive tasks with assurance that they have a level of privacy that can't be achieved at home.

Whether you're looking to speak with clients or prospective employees remotely, private office space and polished meeting rooms have also come to be a status symbol. A video call with chic design elements visible in the background of their office space communicates something powerful – the people in those chairs are invested in the time they spend at work.


Moving into 2021, Houstonians are ready to return to work. Even before the pandemic arrived, commercial real estate was beginning to see that the future of work will be more flexible and more often remote than it was in the past. While we're not through this crisis yet, many professionals are already looking for a new kind of private office arrangement, and local coworking operators are working to deliver the space these Houstonians need.

------

Anish Michael is the CEO of Austin-based Firmspace, which has a 32,000-square-foot space in BBVA Compass Plaza in Houston.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”